Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients-Reference-Cited by-同舟云学术

Immune rebound associates with a favorable clinical response to autologous HSCT in systemic sclerosis patients

Published:2018-01-17 Issue:2 Volume:2 Page:126-141
ISSN:2473-9529
Container-title:Blood Advances
language:en
Short-container-title:

Author:

Arruda Lucas C. M.¹²^ORCID,Malmegrim Kelen C. R.²³^ORCID,Lima-Júnior João R.²⁴,Clave Emmanuel⁵⁶,Dias Juliana B. E.⁷,Moraes Daniela A.⁷,Douay Corinne⁵,Fournier Isabelle⁵,Moins-Teisserenc Hélène⁵⁶,Alberdi Antônio José⁶⁸,Covas Dimas T.²⁷,Simões Belinda P.²⁷,Lansiaux Pauline⁹,Toubert Antoine⁵⁶^ORCID,Oliveira Maria Carolina¹²⁷^ORCID

Affiliation:

1. Basic and Applied Immunology Program, Ribeirão Preto Medical School,

2. Center for Cell-based Therapy, Regional Hemotherapy Center of the Ribeirão Preto Medical School,

3. Department of Clinical, Toxicological and Bromatological Analysis, School of Pharmaceutical Sciences of Ribeirão Preto, and

4. Graduate Program on Bioscience Applied to Pharmacy, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil;

5. INSERM Unité Mixte de Recherche 1160, Institut Universitaire d’Hématologie, Hôpital Saint-Louis, Assistance Publique–Hôpitaux de Paris (AP-HP), Paris, France;

6. Institut Universitaire d'Hématologie, Université Paris Diderot, Sorbonne Paris Cité, Paris, France;

7. Department of Internal Medicine, Ribeirão Preto Medical School, University of São Paulo, Ribeirão Preto, Brazil;

8. Plateforme Technologique, Institut Universitaire d'Hématologie, Paris, France; and

9. Unité de Médecine Interne, Maladies Autoimmunes et Pathologie Vasculaire, UF 04, AP-HP, Centre de référence des maladies auto-immunes systémiques rares d’Ile-de-France (site constitutif), FAI2R, Hôpital Saint-Louis, Paris, France

Abstract

Key Points Clinical response of SSc patients after AHSCT is associated with thymic and bone marrow rebounds. Responder patients showed higher Treg and Breg counts and lower pre-/post-AHSCT TCR repertoire overlap than nonresponder patients.

Publisher

American Society of Hematology

Subject

Hematology

Link

http://ashpublications.org/bloodadvances/article-pdf/2/2/126/879892/advances011072.pdf

Reference72 articles.

1. Systemic sclerosis;Denton;Lancet,2017

2. Scleroderma;Gabrielli;N Engl J Med,2009

3. Effects of cyclophosphamide on pulmonary function in patients with scleroderma and interstitial lung disease: a systematic review and meta-analysis of randomized controlled trials and observational prospective cohort studies;Nannini;Arthritis Res Ther,2008

4. Cyclophosphamide versus placebo in scleroderma lung disease;Tashkin;N Engl J Med,2006

5. Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial;Tashkin;Lancet Respir Med,2016

Cited by 73 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Safety and efficacy of autologous haematopoietic stem-cell transplantation with low-dose cyclophosphamide mobilisation and reduced intensity conditioning versus standard of care in refractory Crohn's disease (ASTIClite): an open-label, multicentre, randomised controlled trial;The Lancet Gastroenterology & Hepatology;2024-04

2. TCRβ clones in muscle tissue share structural features in patients with idiopathic inflammatory myopathy and are associated with disease activity;Frontiers in Immunology;2024-01-10

3. Autologous stem cell transplantation with low-dose cyclophosphamide to improve mucosal healing in adults with refractory Crohn’s disease: the ASTIClite RCT;Efficacy and Mechanism Evaluation;2024-01

4. Autoimmune Disease;The EBMT Handbook;2024

5. Hematopoietic Stem Cell Transplantation;Scleroderma;2024